Products for Research Use Only
RegisterLogin

Purmorphamine (GMP)

CAT: 0804-HY-15108G-01Size: 10 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-15108G-01Size:10 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Purmorphamine (GMP) is Purmorphamine produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. Purmorphamine is a smoothened/Smo receptor agonist with an EC50 of 1 μM[1].
CAS Number
483367-10-8
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Smo
Type
GMP Small Molecules
Related Pathways
Stem Cell/Wnt
Field of Research
Neurological Disease; Cancer
Assay Protocol
https://www.medchemexpress.com/purmorphamine-gmp.html
Purity
99.90
Solubility
10 mM in DMSO
Smiles
N1(C2=CC=C(NC3=NC(OC4=CC=CC5=C4C=CC=C5)=NC6=C3N=CN6C7CCCCC7)C=C2)CCOCC1
Molecular Formula
C31H32N6O2
Molecular Weight
520.62
Precautions
H302, H315, H319, H335
References & Citations
[1]Karumbayaram S, et al. Directed differentiation of human-induced pluripotent stem cells generates active motor neurons. Stem Cells. 2009 Apr;27 (4) :806-11. |[2]Hu Y, et al. Directed differentiation of basal forebrain cholinergic neurons from human pluripotent stem cells. J Neurosci Methods. 2016 Jun 15;266:42-9. |[3]Hua T, et al. Phenotypic, metabolic, and biogenesis properties of human stem cell-derived cerebellar spheroids. Sci Rep. 2022 Jul 27;12 (1) :12880. |[4]Sharma R, et al. 3D Bioprinting Pluripotent Stem Cell Derived Neural Tissues Using a Novel Fibrin Bioink Containing Drug Releasing Microspheres. Front Bioeng Biotechnol. 2020 Feb 11;8:57. |[5]Sundberg M, et al. Improved cell therapy protocols for Parkinson's disease based on differentiation efficiency and safety of hESC-, hiPSC-, and non-human primate iPSC-derived dopaminergic neurons. Stem Cells. 2013 Aug;31 (8) :1548-62.
Shipping Conditions
Blue Ice
Storage Conditions
Keep sealed and protect from light, store at 2-8°C
Scientific Category
GMP Small Molecules
Clinical Information
No Development Reported
Citation 01
Life Sci. 2023 Sep 15:329:121990.|Adv Sci (Weinh) . 2025 May;12 (17) :e2411235.|Am J Physiol Cell Physiol. 2025 Oct 8.|Arthritis Res Ther. 2024 Jan 25;26 (1) :36.|Biochem Biophys Res Commun. 2021 Oct 15:574:1-7.|Burns Trauma. 2019 Sep 23;7:29.|Cancer Med. 2018 Nov;7 (11) :5704-5715.|Cell. 2025 Jun 26;188 (13) :3441-3458.e25.|Int J Mol Sci. 2024 Apr 9, 25 (8), 4138.|J Exp Clin Cancer Res. 2018 Nov 27;37 (1) :287. |J Hazard Mater. 2025 Oct 17:499:140149.|Med Oncol. 2021 Mar 17;38 (4) :41.|Mil Med Res. 2020 Nov 1;7 (1) :52.|Mil Med Res. 2020 Sep 6;7 (1) :42.|Mol Cell Toxicol. 2025 Oct 23.|Oncol Lett. 2019 Sep;18 (3) :3081-3091.|Patent. US20180263995A1.|Pharmacol Res. 2021 Mar:165:105460.|Res Sq. 2025 Apr 24.|Transl Neurodegener. 2024 Oct 29;13 (1) :53.

Related Products

CatalogName
HY-15108-01Purmorphamine
HY-10219G-01Rapamycin (GMP)
HY-N0737AG-01Harmine (GMP)
HY-N0083GBetulin (GMP)
HY-15682G-01TTNPB (GMP)
HY-15794GNemorubicin (GMP)
HY-B1505GAcefylline (GMP)
HY-13506G-01M344 (GMP)
HY-107632GGYY4137 (GMP)
HY-10227GBortezomib (GMP)

Alternative Products

CatalogName
P9199-65Purmorphamine

Popular Products